The Winchester facility has grown through its continued investment in technical expertise and capability, and through employing a flexible business model to support tailored manufacturing solutions for its customers.
Somerset, N.J. (PRWEB) April 16, 2015
Catalent Pharma Solutions, a unit of Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced the opening of a large scale expansion at its Winchester, KY, manufacturing facility, which has seen the doubling of its footprint to 180,000 sq. ft. The expansion features newly installed fluid bed capacity, expanded analytical laboratories, and an advanced, open facility design that provides flexibility in supporting the requirements of new customer programs. The expansion was officially opened by the Lieutenant Governor of Kentucky, the Honourable Crit Luallen, at a ribbon cutting ceremony earlier today.
The expansion was completed in response to increased customer demand for the manufacture of complex, oral solid formulations. Catalent’s Winchester facility has more than 20 years of experience in product development, technology transfer and commercial manufacturing. The site has produced over 3 billion tablets and capsules annually and launched more than 100 new products into the market since its inception.
Speaking at the opening John Chiminski, Catalent’s President & Chief Executive Officer commented: “The Winchester facility has grown through its continued investment in technical expertise and capability, and through employing a flexible business model to support tailored manufacturing solutions for its customers. This flexibility, along with our proven track record of success with technology transfers and product launches, has clearly driven increased demand for manufacturing services at Winchester, and our latest capacity expansion allows us to manufacture substantial marketed products for both new and existing customers.”
Opened in 1992, Catalent’s Winchester facility has evolved into one of the industry’s premier sites for advanced oral controlled-release drug formulation and manufacturing. Construction work on the expansion began in 2013 with a $35M facility investment, followed by a subsequent investment in additional fluid bed capacity. The expansion will add as many as 140 new employees at the site, with potential to add further employees and capabilities as customer demand for Winchester’s manufacturing solutions continues to grow.
Notes for Editors
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,500 people, including over 1,000 scientists, at 30 facilities across 5 continents, and in fiscal 2014 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit http://www.catalent.com
More products. Better treatments. Reliably supplied.™